MDCO News and Press, The Medicines Company From 03/21/19

The following slide deck was published by The Medicines Company in conjunction with this Read more ...

The last twelve months haven’t been particularly good in terms of market performance for Alnylam Pharmaceuticals ( ALNY ), and that hasn’t really changed much over the last three months either, as the shares continue to lag biotech indices. With top-line Phase III givosiran da...

Never forget your past for your future as one day your future will again be your past " - Mizan Chaudhury We continue with our new weekly feature today. Every week, we will be providing very brief overviews of five interesting stocks insiders are currently buying. I have always found insi...

InsiderInsights' Daily Round-Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signi...

Insider buying decreased significantly last week with insiders purchasing $158.33 million of stock compared to $314.42 million in the week prior. Selling on the other hand increased with insiders selling $3.8 billion of stock last week compared to $2.09 billion in the week prior. A large part ...

InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi...

The following slide deck was published by The Medicines Company in conjunction with this Read more ...

The Medicines Company (MDCO) Q4 2018 Results Earnings Conference Call February 27, 2019, 08:30 AM ET Company Participants Krishna Gorti - VP, IR Mark Timney - CEO Christopher Visioli - CFO Peter Wijngaard - CDO Conference Call Participants Jessica Fye - JPMorgan Umer Ra...

Continued progress in inclisiran’s development, with no material safety issues to date, paves the way for topline pivotal trial readouts expected in 3Q Inclisiran’s unique profile, vast global market opportunity and long-dated exclusivity set the stage for significant ...

AES , AMRN , AMT , ANIP , BBY , CHK , CLH , CPB , DF , DNR , DOC , DY , EYE , FTDR , GCP , GTE , HMLP , HPT , HZNP , IONS , LIVN , LOW , LXP , MDCO , MGPI , MIDD , NEWM , NOVT , OCN , ODP , PEG , PGTI , PNM , RDC , SBGI , SHOO , TAST , TJX , UTHR F...